Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 35

1.

Minimal clinically important difference of improvement on the Arm Function in Multiple Sclerosis Questionnaire (AMSQ).

van Munster CE, Kaya L, Obura M, Kalkers NF, Uitdehaag BM.

Mult Scler. 2019 Jan 18:1352458518823489. doi: 10.1177/1352458518823489. [Epub ahead of print]

PMID:
30657002
2.

Autonomic Dysregulation, Cognitive Impairment, and Symptoms of Psychosis as an Unusual Presentation in an Anti-Aquaporin 4-Positive Patient.

Ruiter AM, Meilof JF, Somanje-Bolweg RRJ, van Gorsel E, Kalkers NF.

Case Rep Neurol. 2017 Feb 6;9(1):12-16. doi: 10.1159/000455942. eCollection 2017 Jan-Apr.

3.

Motor evoked potential: a reliable and objective measure to document the functional consequences of multiple sclerosis? Relation to disability and MRI.

Kalkers NF, Strijers RL, Jasperse MM, Neacsu V, Geurts JJ, Barkhof F, Polman CH, Stam CJ.

Clin Neurophysiol. 2007 Jun;118(6):1332-40. Epub 2007 Mar 29.

PMID:
17398151
4.

Determinants of cerebral atrophy rate at the time of diagnosis of multiple sclerosis.

Jasperse B, Minneboo A, de Groot V, Kalkers NF, van Helden PE, Uitdehaag BM, Barkhof F, Polman CH.

Arch Neurol. 2007 Feb;64(2):190-4.

PMID:
17296834
5.

Cognitive impairment and decline in different MS subtypes.

Huijbregts SC, Kalkers NF, de Sonneville LM, de Groot V, Polman CH.

J Neurol Sci. 2006 Jun 15;245(1-2):187-94. Epub 2006 Apr 27. Review.

PMID:
16643951
6.

Long-term clinical outcome of primary progressive MS: predictive value of clinical and MRI data.

Sastre-Garriga J, Ingle GT, Rovaris M, Téllez N, Jasperse B, Altmann DR, Benedetti B, Stevenson VL, Cercignani M, Leary SM, Barkhof F, Brochet B, Dousset V, Filippi M, Montalban X, Kalkers NF, Polman CH, Rovira A, Miller DH, Thompson AJ.

Neurology. 2005 Aug 23;65(4):633-5.

PMID:
16116134
7.

A longitudinal study of cognition in primary progressive multiple sclerosis.

Camp SJ, Stevenson VL, Thompson AJ, Ingle GT, Miller DH, Borras C, Brochet B, Dousset V, Falautano M, Filippi M, Kalkers NF, Montalban X, Polman CH, Langdon DW.

Brain. 2005 Dec;128(Pt 12):2891-8. Epub 2005 Jul 27.

PMID:
16049040
8.

Glutamate inhibition in MS: the neuroprotective properties of riluzole.

Killestein J, Kalkers NF, Polman CH.

J Neurol Sci. 2005 Jun 15;233(1-2):113-5. Epub 2005 Apr 20.

PMID:
15949499
9.

Expression of adhesion molecules on peripheral lymphocytes predicts future lesion development in MS.

Eikelenboom MJ, Killestein J, Izeboud T, Kalkers NF, Baars PA, van Lier RA, Barkhof F, Uitdehaag BM, Polman CH.

J Neuroimmunol. 2005 Jan;158(1-2):222-30.

PMID:
15589057
10.

Differences in cognitive impairment of relapsing remitting, secondary, and primary progressive MS.

Huijbregts SC, Kalkers NF, de Sonneville LM, de Groot V, Reuling IE, Polman CH.

Neurology. 2004 Jul 27;63(2):335-9.

PMID:
15277630
11.

Patients with multiple sclerosis prefer early diagnosis.

Janssens AC, de Boer JB, Kalkers NF, Passchier J, van Doorn PA, Hintzen RQ.

Eur J Neurol. 2004 May;11(5):335-7.

PMID:
15142227
12.

The patient's perception of a (reliable) change in the Multiple Sclerosis Functional Composite.

Hoogervorst EL, Kalkers NF, Cutter GR, Uitdehaag BM, Polman CH.

Mult Scler. 2004 Feb;10(1):55-60.

PMID:
14760953
13.

The interleukin-1 gene family in multiple sclerosis susceptibility and disease course.

Hooper-van Veen T, Schrijver HM, Zwiers A, Crusius JB, Knol DL, Kalkers NF, Laine ML, Barkhof F, Peña AS, Polman CH, Uitdehaag BM.

Mult Scler. 2003 Dec;9(6):535-9.

PMID:
14664464
14.

[Alpha]B-crystallin genotype has impact on the multiple sclerosis phenotype.

van Veen T, van Winsen L, Crusius JB, Kalkers NF, Barkhof F, Peña AS, Polman CH, Uitdehaag BM.

Neurology. 2003 Nov 11;61(9):1245-9.

PMID:
14610128
15.

Cytokine producing CD8+ T cells are correlated to MRI features of tissue destruction in MS.

Killestein J, Eikelenboom MJ, Izeboud T, Kalkers NF, Adèr HJ, Barkhof F, Van Lier RA, Uitdehaag BM, Polman CH.

J Neuroimmunol. 2003 Sep;142(1-2):141-8.

PMID:
14512173
16.

Anxiety and depression influence the relation between disability status and quality of life in multiple sclerosis.

Janssens AC, van Doorn PA, de Boer JB, Kalkers NF, van der Meche FG, Passchier J, Hintzen RQ.

Mult Scler. 2003 Aug;9(4):397-403.

PMID:
12926846
17.

The effect of the neuroprotective agent riluzole on MRI parameters in primary progressive multiple sclerosis: a pilot study.

Kalkers NF, Barkhof F, Bergers E, van Schijndel R, Polman CH.

Mult Scler. 2002 Dec;8(6):532-3.

PMID:
12474997
18.

Chemokine receptor expression on T cells is related to new lesion development in multiple sclerosis.

Eikelenboom MJ, Killestein J, Izeboud T, Kalkers NF, van Lier RA, Barkhof F, Uitdehaag BM, Polman CH.

J Neuroimmunol. 2002 Dec;133(1-2):225-32.

PMID:
12446027
19.

Longitudinal brain volume measurement in multiple sclerosis: rate of brain atrophy is independent of the disease subtype.

Kalkers NF, Ameziane N, Bot JC, Minneboo A, Polman CH, Barkhof F.

Arch Neurol. 2002 Oct;59(10):1572-6.

PMID:
12374494
20.

Brain atrophy in multiple sclerosis: impact of lesions and of damage of whole brain tissue.

Kalkers NF, Vrenken H, Uitdehaag BM, Polman CH, Barkhof F.

Mult Scler. 2002 Oct;8(5):410-4.

PMID:
12356208
21.

Multiple sclerosis functional composite: impact of reference population and interpretation of changes.

Uitdehaag BM, Adèr HJ, Roosma TJ, de Groot V, Kalkers NF, Polman CH.

Mult Scler. 2002 Oct;8(5):366-71.

PMID:
12356201
22.

Quantitative functional measures in MS: what is a reliable change?

Uitdehaag BM, Adèr HJ, Kalkers NF, Polman CH.

Neurology. 2002 Aug 27;59(4):648-9; author reply 649. No abstract available.

PMID:
12196675
23.

The FAS-670 polymorphism influences susceptibility to multiple sclerosis.

van Veen T, Kalkers NF, Crusius JB, van Winsen L, Barkhof F, Jongen PJ, Peña AS, Polman CH, Uitdehaag BM.

J Neuroimmunol. 2002 Jul;128(1-2):95-100.

PMID:
12098516
24.

Production of IL-1beta and IL-1Ra as risk factors for susceptibility and progression of relapse-onset multiple sclerosis.

de Jong BA, Huizinga TW, Bollen EL, Uitdehaag BM, Bosma GP, van Buchem MA, Remarque EJ, Burgmans AC, Kalkers NF, Polman CH, Westendorp RG.

J Neuroimmunol. 2002 May;126(1-2):172-9.

PMID:
12020968
25.

Safety, tolerability, and efficacy of orally administered cannabinoids in MS.

Killestein J, Hoogervorst EL, Reif M, Kalkers NF, Van Loenen AC, Staats PG, Gorter RW, Uitdehaag BM, Polman CH.

Neurology. 2002 May 14;58(9):1404-7.

PMID:
12011290
26.

Two-year follow-up study of primary and transitional progressive multiple sclerosis.

Ingle GT, Stevenson VL, Miller DH, Leary SM, Rovaris M, Barkhof F, Brochet B, Dousset V, Filippi M, Montalban X, Kalkers NF, Polman CH, Rovira A, Thompson AJ.

Mult Scler. 2002 Apr;8(2):108-14.

PMID:
11990866
27.

A study validating changes in the multiple sclerosis functional composite.

Hoogervorst EL, Kalkers NF, Uitdehaag BM, Polman CH.

Arch Neurol. 2002 Jan;59(1):113-6.

PMID:
11790238
28.

Differential treatment effect on measures of neurologic exam, functional impairment and patient self-report in multiple sclerosis.

Hoogervorst EL, Kalkers NF, van Winsen LML, Uitdehaag BM, Polman CH.

Mult Scler. 2001 Oct;7(5):335-9.

PMID:
11724450
29.

Optimizing the association between disability and biological markers in MS.

Kalkers NF, Bergers E, Castelijns JA, van Walderveen MA, Bot JC, Adèr HJ, Polman CH, Barkhof F.

Neurology. 2001 Oct 9;57(7):1253-8.

PMID:
11591845
30.

TNFalpha production by CD4(+) T cells predicts long-term increase in lesion load on MRI in MS.

Killestein J, Kalkers NF, Meilof JF, Barkhof F, van Lier RA, Polman CH.

Neurology. 2001 Sep 25;57(6):1129-31.

PMID:
11571353
31.

The brief repeatable battery of neuropsychological tests: normative values allow application in multiple sclerosis clinical practice.

Boringa JB, Lazeron RH, Reuling IE, Adèr HJ, Pfennings L, Lindeboom J, de Sonneville LM, Kalkers NF, Polman CH.

Mult Scler. 2001 Aug;7(4):263-7.

PMID:
11548987
32.

Comparisons of patient self-report, neurologic examination, and functional impairment in MS.

Hoogervorst EL, van Winsen LM, Eikelenboom MJ, Kalkers NF, Uitdehaag BM, Polman CH.

Neurology. 2001 Apr 10;56(7):934-7.

PMID:
11294932
33.

Magnetization transfer histogram parameters reflect all dimensions of MS pathology, including atrophy.

Kalkers NF, Hintzen RQ, van Waesberghe JH, Lazeron RH, van Schijndel RA, Adèr HJ, Polman CH, Barkhof F.

J Neurol Sci. 2001 Mar 1;184(2):155-62. Erratum in: J Neurol Sci 2001 Jun 15;187(1-2):111.

PMID:
11239950
34.

Concurrent validity of the MS Functional Composite using MRI as a biological disease marker.

Kalkers NF, Bergers L, de Groot V, Lazeron RH, van Walderveen MA, Uitdehaag BM, Polman CH, Barkhof F.

Neurology. 2001 Jan 23;56(2):215-9.

PMID:
11160958
35.

MS functional composite: relation to disease phenotype and disability strata.

Kalkers NF, de Groot V, Lazeron RH, Killestein J, Adèr HJ, Barkhof F, Lankhorst GJ, Polman CH.

Neurology. 2000 Mar 28;54(6):1233-9.

PMID:
10746590

Supplemental Content

Loading ...
Support Center